ESC Guideline Recommendations for Management of NSTEMI
Initial Assessment and Diagnosis
- Obtain a 12‑lead ECG within 10 minutes of first medical contact and have it interpreted immediately by an experienced clinician (Class I, Level A) 1.
- Measure high‑sensitivity cardiac troponin at presentation (0 h) and again at 1 h using the ESC 0 h/1 h algorithm for rapid rule‑in/rule‑out of NSTEMI (Class I, Level A) 1.
- If the first two troponin results are inconclusive but clinical suspicion remains high, repeat the measurement at 3 h (Class I, Level A) 1.
Immediate Antiplatelet Therapy
- All patients with suspected NSTEMI should receive immediate dual antiplatelet therapy: aspirin 150–300 mg loading (followed by 75–100 mg daily) plus a P2Y12 inhibitor, together with parenteral anticoagulation, before risk stratification for invasive timing (Class I, Level A) 1, 2.
Anticoagulation Strategy
- Fondaparinux is the preferred anticoagulant for patients managed conservatively because of its favorable bleeding profile (Class I, Level A) 1.
- Enoxaparin is preferred over unfractionated heparin when renal function is adequate and CABG is not planned within 24 h (Class I, Level A) 3.
- Unfractionated heparin (UFH) should be used when early CABG is anticipated, owing to its rapid reversibility (Class I, Level A) 4, 3.
- Bivalirudin (0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion) is recommended as an alternative to UFH plus GP IIb/IIIa inhibitors during PCI (Class IIa, Level A) 1, 2.
- UFH should be continued for at least 48 h or until discharge (Class I, Level A) 4.
- Enoxaparin or fondaparinux may be continued for the duration of hospitalization, up to 8 days (Class I, Level A) 4.
Risk Stratification and Timing of Invasive Strategy
- Apply the GRACE risk score for prognostic assessment and to guide timing of coronary angiography (Class I, Level A) 1, 2.
- An early invasive strategy (angiography ≤ 24 h) is indicated for patients with mechanical complications of MI, recurrent or ongoing chest pain with ST‑segment changes, or a high‑risk GRACE score (Class I, Level A) 5, 2.
- A conservative strategy may be appropriate for patients with low GRACE scores, significant comorbidities outweighing invasive risk, or prior imaging showing no obstructive CAD (Class IIa, Level B) 4.
- The EARLY‑ACS trial showed that routine upstream GP IIb/IIIa inhibitor therapy before angiography does not reduce ischemic events but increases major bleeding (2.6 % vs 1.8 %; p = 0.02); therefore GP IIb/IIIa inhibitors should be deferred until angiography unless refractory ischemia is present (Class III, Level A) 6.
Post‑Angiography Management
After PCI
- Continue aspirin indefinitely (Class I, Level A) 4.
- Give a P2Y12‑inhibitor loading dose if it was not administered before angiography (Class I, Level A) 4.
- Discontinue anticoagulation after an uncomplicated PCI (Class I, Level A) 4.
When CABG Is Planned
- Continue aspirin throughout the peri‑operative period (Class I, Level A) 4.
- Stop clopidogrel 5–7 days before surgery (Class I, Level A) 4.
- Discontinue bivalirudin 3 hours before CABG and substitute UFH according to institutional protocol (Class I, Level A) 4.
When Managed Medically
- Continue aspirin indefinitely (Class I, Level A) 4.
- Administer a P2Y12‑inhibitor loading dose if not given before angiography (Class I, Level A) 4.
- Stop any GP IIb/IIIa inhibitor that was started earlier (Class I, Level A) 4.
- Maintain anticoagulation for the duration specified above (Class I, Level A) 4.
Long‑Term Pharmacotherapy
- Initiate high‑intensity statin therapy in all NSTEMI patients for secondary prevention (Class I, Level A) 5.
- Consider extending dual antiplatelet therapy beyond 12 months after a careful balance of ischemic versus bleeding risk, especially in patients with very high ischemic risk and acceptable bleeding risk (Class IIb, Level B) 1.
Special Considerations
- In patients already on therapeutic warfarin (INR ≥ 2.0) at presentation, defer additional anticoagulant therapy until INR falls below 2.0, but start antiplatelet therapy regardless of INR (Class I, Level A) 4.
Management of Non-ST-Elevation Myocardial Infarction (NSTEMI)
Initial Evaluation and Diagnosis
- The European Society of Cardiology recommends performing a 12-lead ECG within 10 minutes of first medical contact and having it immediately interpreted by an experienced physician 7
- Obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty 7
- Measure high-sensitivity cardiac troponin (hs-cTn) at admission (0h) and 1 hour later (ESC 0h/1h algorithm) for diagnosis and prognostic evaluation 7, 8
- If the first two troponin measurements are not conclusive and the clinical situation still suggests an acute coronary syndrome, perform an additional test after 3 hours 7
- Perform an echocardiogram to evaluate left ventricular regional and global function 7, 8
Antiplatelet Therapy
- Administer aspirin to all patients without contraindications at a loading dose of 150-300 mg orally, followed by a maintenance dose of 75-100 mg per day long-term 7, 9
- Add a P2Y12 receptor inhibitor to aspirin and maintain it for 12 months, unless contraindicated or at high risk of bleeding 7, 8
- Options for P2Y12 inhibitors:
- Ticagrelor (loading dose 180 mg, 90 mg twice daily) regardless of the planned treatment strategy (invasive or conservative) 7
- Prasugrel (loading dose 60 mg, standard dose 10 mg/day, 5 mg/day for patients ≥75 years or with weight <60 kg) in patients naive to P2Y12 inhibitors undergoing invasive coronary procedures 7
- Clopidogrel (loading dose 300-600 mg, daily dose 75 mg), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated 7
Anticoagulant Therapy
- Administer parenteral anticoagulation to all NSTEMI patients in addition to antiplatelet therapy 7, 9
- Options for anticoagulation:
- For medically treated patients, continue intravenous UFH for at least 48 hours or until discharge if administered before diagnostic angiography 9
- Continue enoxaparin or fondaparinux for the duration of hospitalization, up to 8 days, if administered before diagnostic angiography 9
Selection of Management Strategy
- An early invasive strategy (angiography within 24-48 hours) is indicated for patients with:
- A conservative strategy is appropriate for low-risk patients without ongoing ischemia or for patients with significant comorbidities where the risks of an invasive approach outweigh the benefits 9
Post-Angiography Management
- If percutaneous coronary intervention (PCI) is selected:
- If coronary artery bypass grafting (CABG) is selected:
Long-Term Management
- Measure left ventricular ejection fraction (LVEF) 9
- If LVEF ≤0.40, consider diagnostic angiography 9
- If LVEF >0.40, consider a stress test 10, 9
- Initiate ACE inhibitors for patients with heart failure, left ventricular dysfunction (LVEF <0.40), hypertension, or diabetes 8, 9
- Consider angiotensin II receptor blockers (ARBs) for patients intolerant to ACE inhibitors 9
- Initiate beta-blockers for all NSTEMI patients without contraindications 8, 9
Guideline Recommendations for the Management of NSTEMI
Immediate Dual Antiplatelet and Anticoagulation Therapy
- All patients with NSTEMI should receive immediate dual antiplatelet therapy (aspirin + a P2Y12 inhibitor) and parenteral anticoagulation, followed by risk stratification to schedule coronary angiography within 2–24 h; high‑risk patients proceed to an early invasive strategy. 11
Antiplatelet Therapy
Aspirin
- Give a loading dose of 150–325 mg (non‑enteric‑coated, chewable preferred) immediately, then continue 75–100 mg daily indefinitely. 12, 11
P2Y12 Inhibitors
- Ticagrelor is the preferred agent: 180 mg loading dose, then 90 mg twice daily. 12, 11
- Prasugrel may be used when PCI is planned: 60 mg loading dose, then 10 mg daily (reduce to 5 mg daily if age ≥ 75 yr or weight < 60 kg). 12
Anticoagulation (Evidence‑Based Options)
- Unfractionated heparin is indicated when CABG is anticipated within 24 h or in severe renal dysfunction: 60–70 U/kg IV bolus (max 5 000 U), then infusion 12–15 U/kg/h (max 1 000 U/h), targeting an aPTT of 1.5–2.5 × control. 13
Additional Acute Therapies
- Oxygen should be administered only if SpO₂ < 90 % or the patient has respiratory distress. 13
- Nitroglycerin: sublingual 0.4 mg every 5 min × 3 doses, then IV infusion if ischemia persists; contraindicated with SBP < 90 mmHg, right‑ventricular infarction, or recent phosphodiesterase‑inhibitor use. 14, 13
- Morphine 2–4 mg IV for refractory chest pain not relieved by nitrates. 14
Risk Stratification and Timing of Invasive Strategy
Very High‑Risk (Immediate Angiography < 2 h)
- Recurrent or refractory angina despite maximal medical therapy. 13, 15
- Life‑threatening ventricular arrhythmias or cardiac arrest. 14, 13
- Acute heart failure with pulmonary edema. 14, 13
High‑Risk (Early Invasive 12–24 h)
- Dynamic ST‑segment or T‑wave changes (≥0.05 mV depression). 14, 13
- Elevated cardiac troponin. 14, 13
- Left ventricular ejection fraction < 40 %. 14, 13
- Prior PCI within 6 months or prior CABG. 12, 14
Intermediate‑Risk (Invasive 24–72 h)
Low‑Risk (Conservative Strategy, Selective Angiography)
- No recurrent chest pain. 14, 13
- No signs of heart failure. 14, 13
- Normal or minimally elevated troponin. 14
Invasive Procedure Recommendations
- Radial access is preferred over femoral to reduce bleeding, vascular complications, and mortality. 11
- Complete revascularization is recommended for NSTEMI patients with multivessel disease; multivessel PCI may be performed during the index procedure or staged (single‑procedure preferred). 11
Periprocedural Antiplatelet Management for PCI
- Continue aspirin throughout PCI. 12, 14
- Administer a P2Y12‑inhibitor loading dose if not given earlier. 14
- GP IIb/IIIa inhibitors (eptifibatide, tirofiban, or abciximab) are indicated for high‑risk patients with elevated troponin undergoing PCI. 12, 13, 15
Management When CABG Is Planned
- Continue aspirin throughout the peri‑operative period. 14
- Discontinue clopidogrel 5–7 days before surgery. 14
Long‑Term Dual Antiplatelet Therapy (Post‑Discharge)
- Aspirin 75–100 mg daily indefinitely. 12, 11
- Continue the chosen P2Y12 inhibitor for at least 12 months as the default strategy. 11
- Consider ticagrelor monotherapy (stop aspirin) ≥1 month after PCI in patients who have tolerated DAPT, to lower bleeding risk. 11
Secondary Prevention and Supportive Care
- Prescribe a proton‑pump inhibitor for patients at risk of gastrointestinal bleeding. 11
- Refer all patients to cardiac rehabilitation; home‑based programs are acceptable when in‑person attendance is not feasible. 11
- Obtain a fasting lipid panel 4–8 weeks after initiating or adjusting lipid‑lowering therapy. 11
Contraindications and Safety Alerts
- Fibrinolysis is contraindicated in NSTEMI; meta‑analyses show no benefit and an increased risk of myocardial infarction. 13, 15
- Non‑steroidal anti‑inflammatory drugs (NSAIDs) and COX‑2 inhibitors increase mortality, reinfarction, and cardiac rupture; they should be discontinued. 16
- Early invasive strategy should be avoided in patients with extensive comorbidities where procedural risk outweighs benefit (severe liver/pulmonary failure, active malignancy, terminal illness), in those who refuse revascularization, or when the likelihood of ACS is low. 13, 15
- Do not use a lower aspirin maintenance dose (81 mg) during the acute phase; 81 mg daily is reasonable only after PCI. 12